Inactive Instrument

News Organovo Holdings Inc Nyse

Equities

US68620A1043

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 15	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
Apr. 15	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 16	AQ
Organovo's fatty liver disease drug meets main goal in mid-stage study	Apr. 15	RE
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 15	AQ
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 15	CI
Organovo: Fiscal Q3 Earnings Snapshot	Feb. 08	AQ
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	Jan. 25	AQ
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	Jan. 25	CI
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	Jan. 09	AQ
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	Dec. 06	AQ
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	Dec. 06	CI
Organovo: Fiscal Q2 Earnings Snapshot	Nov. 10	AQ
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Organovo Highlights FXR314 Combination Therapy Potential and Plan	Nov. 08	AQ
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	Nov. 08	CI
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	Nov. 03	PU
Organovo to Participate in the H.C. Wainwright Global Investment Conference	23-09-08	AQ
Organovo : Change in Certifying Accountants - Form 8-K	23-09-05	PU
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23	AQ
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Organovo Holdings Inc Nyse

Equities

US68620A1043

Summary

Filters